NOT FOR DISTRIBUTION
Header cover image

Market Cap

kr.1.1t

Last Updated

2021/05/13 18:34 UTC

Data Sources

Company Financials +

Executive Summary

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. More Details


Snowflake Analysis

Proven track record with adequate balance sheet and pays a dividend.


Similar Companies

Share Price & News

How has Novo Nordisk's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NOVO B is less volatile than 75% of Danish stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: NOVO B's weekly volatility (3%) has been stable over the past year.


Market Performance


7 Day Return

5.1%

NOVO B

1.4%

DK Pharmaceuticals

-0.6%

DK Market


1 Year Return

9.0%

NOVO B

-3.3%

DK Pharmaceuticals

30.7%

DK Market

Return vs Industry: NOVO B exceeded the Danish Pharmaceuticals industry which returned -3.6% over the past year.

Return vs Market: NOVO B underperformed the Danish Market which returned 29.6% over the past year.


Shareholder returns

NOVO BIndustryMarket
7 Day5.1%1.4%-0.6%
30 Day8.7%2.1%0.5%
90 Day4.1%1.1%0.8%
1 Year11.4%9.0%-0.3%-3.3%34.0%30.7%
3 Year65.7%54.7%32.1%17.1%58.3%46.2%
5 Year52.0%34.1%45.1%20.9%79.1%55.6%

Long-Term Price Volatility Vs. Market

How volatile is Novo Nordisk's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Novo Nordisk undervalued compared to its fair value and its price relative to the market?

33.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: NOVO B (DKK478.85) is trading below our estimate of fair value (DKK716.94)

Significantly Below Fair Value: NOVO B is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: NOVO B is poor value based on its PE Ratio (26x) compared to the European Pharmaceuticals industry average (25.2x).

PE vs Market: NOVO B is poor value based on its PE Ratio (26x) compared to the Danish market (17.2x).


Price to Earnings Growth Ratio

PEG Ratio: NOVO B is poor value based on its PEG Ratio (3.4x)


Price to Book Ratio

PB vs Industry: NOVO B is overvalued based on its PB Ratio (18.9x) compared to the XE Pharmaceuticals industry average (3.3x).


Future Growth

How is Novo Nordisk forecast to perform in the next 1 to 3 years based on estimates from 27 analysts?

7.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NOVO B's forecast earnings growth (7.6% per year) is above the savings rate (0.1%).

Earnings vs Market: NOVO B's earnings (7.6% per year) are forecast to grow slower than the Danish market (9.6% per year).

High Growth Earnings: NOVO B's earnings are forecast to grow, but not significantly.

Revenue vs Market: NOVO B's revenue (7.1% per year) is forecast to grow faster than the Danish market (7% per year).

High Growth Revenue: NOVO B's revenue (7.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NOVO B's Return on Equity is forecast to be very high in 3 years time (65.9%).


Past Performance

How has Novo Nordisk performed over the past 5 years?

2.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NOVO B has a high level of non-cash earnings.

Growing Profit Margin: NOVO B's current net profit margins (33.8%) are higher than last year (31.9%).


Past Earnings Growth Analysis

Earnings Trend: NOVO B's earnings have grown by 2.8% per year over the past 5 years.

Accelerating Growth: NOVO B's earnings growth over the past year (6.1%) exceeds its 5-year average (2.8% per year).

Earnings vs Industry: NOVO B earnings growth over the past year (6.1%) underperformed the Pharmaceuticals industry 6.7%.


Return on Equity

High ROE: NOVO B's Return on Equity (73.3%) is considered outstanding.


Financial Health

How is Novo Nordisk's financial position?


Financial Position Analysis

Short Term Liabilities: NOVO B's short term assets (DKK61.4B) do not cover its short term liabilities (DKK72.4B).

Long Term Liabilities: NOVO B's short term assets (DKK61.4B) exceed its long term liabilities (DKK10.5B).


Debt to Equity History and Analysis

Debt Level: NOVO B's debt to equity ratio (10.3%) is considered satisfactory.

Reducing Debt: NOVO B's debt to equity ratio has increased from 1.1% to 10.3% over the past 5 years.

Debt Coverage: NOVO B's debt is well covered by operating cash flow (879.5%).

Interest Coverage: NOVO B earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Novo Nordisk current dividend yield, its reliability and sustainability?

1.90%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: NOVO B's dividend (1.9%) is higher than the bottom 25% of dividend payers in the Danish market (1.15%).

High Dividend: NOVO B's dividend (1.9%) is low compared to the top 25% of dividend payers in the Danish market (3.4%).


Stability and Growth of Payments

Stable Dividend: NOVO B's dividend payments have been volatile in the past 10 years.

Growing Dividend: NOVO B's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (49.3%), NOVO B's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: NOVO B's dividends in 3 years are forecast to be well covered by earnings (49% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Lars Jorgensen (54 yo)

4.33yrs

Tenure

kr.56,500,000

Compensation

Mr. Lars Fruergaard Jorgensen has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member of Management Board. He has been Deputy Chair of the Supervisory ...


CEO Compensation Analysis

Compensation vs Market: Lars's total compensation ($USD9.18M) is above average for companies of similar size in the Danish market ($USD3.73M).

Compensation vs Earnings: Lars's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: NOVO B's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: NOVO B's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Novo Nordisk A/S's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Novo Nordisk A/S
  • Ticker: NOVO B
  • Exchange: CPSE
  • Founded: 1923
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr.1.101t
  • Shares outstanding: 2.30b
  • Website: https://www.novonordisk.com

Number of Employees


Location

  • Novo Nordisk A/S
  • Novo Allé
  • Bagsvaerd
  • Capital Region of Denmark
  • 2880
  • Denmark

Listings


Biography

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Bi...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/13 18:34
End of Day Share Price2021/05/12 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.